article thumbnail

The 20 Key Moments in the 340B Program's 30-Year History

Omnicell

2011: The Government Accountability Office (GAO) published a study entitled: "Drug Pricing: Manufacturer Discounts in the 340B Program Offer Benefits, but Federal Oversight Needs Improvement." Also, in 2011, the U.S. However, lawmakers decided that it was not needed anymore since HRSA was expanding the program on its own.

article thumbnail

Skinny Label and Induced Infringement: The Saga Continues

The FDA Law Blog

No reasonable jury could have concluded that the carved-out labeling for petitioner’s generic carvedilol from 2007-2011 was itself evidence of intent to induce infringement.” However, the Government’s suggestion that the facts will be similar across skinny label cases is flatly denied by GSK in the pleadings.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New regulatory relief to benefit Europe’s pharma SMEs

European Pharmaceutical Review

As small and medium-sized enterprises (SMEs) often face unfair competition when doing business in Europe, through the (SME) Relief Communication, the European Commission (EC) has proposed new measures to provide short-term relief, boost long-term competitiveness, and improve equality in the business environment across the Single Market in Europe.

article thumbnail

CMC Requirements for New Drug Registration in Latin America

ISPE

Improvements have been observed by various regulatory agencies in Latin America for the acceptance and implementation of international standards—for instance, the ICH Common Technical Document (CTD) format. Additional required information beyond ICH guidelines, or non-value-added documents (e.g., 6, and 2.3.S.7 7 are required.

article thumbnail

Considerations for a Decentralized Manufacturing Paradigm

ISPE

Nature Communications 12, no. Subsequently, the new data is authored into Module 3 (Quality) of the Common Technical Document and submitted separately to multiple health authorities worldwide for approval. Biotechnology Progress 36, no. 3 (2020):e2970. 34 Maschan, M., 1 (2021):7200. 35 Anguille, S., 36 Sterling, J. 22 March 2018.

article thumbnail

SPuMoNI: Enhancing Pharma Data Quality through Smart Technologies

ISPE

Although the pharmaceutical industry has consistently improved manufacturing processes 3 in compliance with good manufacturing practices, 4 there are documented deviations from good practices 5 including the continued falsification of medicines. Directive 2011/62/EU of the European Parliament and of the Council.” Published 2011.

Dosage 52
article thumbnail

Accommodating Multiple Modalities in the Same Facility

ISPE

Other industry best practices may not be formally documented in regulations or industry best practice guides, but should also be investigated as part of the assessment. Published December 2011. You may unsubscribe from these ISPE communications at any time. The assessment may also identify perception concerns.